Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 9/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | TOP2A | P11388 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4256965 | 0.92 | MAPT (0.51) | SMN1; SMN2HTTMAPTKMT2AMEN1 | |
| SCHEMBL4252071 | 0.89 | KDM4E (0.48) | SMN1; SMN2HTTMAPTKMT2AMEN1 | |
| SCHEMBL4253805 | 0.89 | SMN1; SMN2 (0.45) | SMN1; SMN2HTTMAPTKMT2AMEN1 | |
| SCHEMBL4254591 | 0.88 | TP53 (0.54) | SMN1; SMN2HTTMAPTKMT2AMEN1 | |
| SCHEMBL4252395 | 0.85 | MAPT (0.48) | SMN1; SMN2HTTMAPTKMT2AMEN1 | |
| SCHEMBL4249281 | 0.85 | POLB (0.62) | SMN1; SMN2HTTMAPTKMT2AMEN1 | |
| SCHEMBL4252566 | 0.85 | POLB (0.55) | HTTMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL4256982 | 0.85 | MYB (0.61) | SMN1; SMN2HTTMAPTKMT2AMEN1 | |
| SCHEMBL4249301 | 0.84 | MAPT (0.63) | SMN1; SMN2HTTMAPTKMT2AMEN1 | |
| SCHEMBL4259496 | 0.84 | MAPT (0.50) | MAPTKMT2AMEN1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349864-B2 | Pyrano [3,2-C] pyridones and related heterocyclic compounds as pharmaceutical agents for treating disorders responsive to apoptosis, antiproliferation or vascular disruption, and the use thereof | NEW MEXICO TECHNICAL RESEARCH FOUNDATION (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349864-B2 | Pyrano [3,2-C] pyridones and related heterocyclic compounds as pharmaceutical agents for treating disorders responsive to apoptosis, antiproliferation or vascular disruption, and the use thereof | NEW MEXICO TECHNICAL RESEARCH FOUNDATION (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349864-B2 | Pyrano [3,2-C] pyridones and related heterocyclic compounds as pharmaceutical agents for treating disorders responsive to apoptosis, antiproliferation or vascular disruption, and the use thereof | NEW MEXICO TECHNICAL RESEARCH FOUNDATION (US) | 2013-01-08 | — | — | US | disclosed |
| US-20090247566-A1 | Pyrano [3,2-C] Pyridones and Related Heterocyclic Compounds as Pharmaceutical Agents for Treating Disorders Responsive to Apoptosis, Antiproliferation or Vascular Disruption, and the Use Thereof | NEW MEXICO TECHNICAL RESEARCH FOUNDATION | 2009-10-01 | — | — | US | disclosed |
| US-20090247566-A1 | Pyrano [3,2-C] Pyridones and Related Heterocyclic Compounds as Pharmaceutical Agents for Treating Disorders Responsive to Apoptosis, Antiproliferation or Vascular Disruption, and the Use Thereof | NEW MEXICO TECHNICAL RESEARCH FOUNDATION | 2009-10-01 | — | — | US | disclosed |
| US-20090247566-A1 | Pyrano [3,2-C] Pyridones and Related Heterocyclic Compounds as Pharmaceutical Agents for Treating Disorders Responsive to Apoptosis, Antiproliferation or Vascular Disruption, and the Use Thereof | NEW MEXICO TECHNICAL RESEARCH FOUNDATION | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247566-A1 | Pyrano [3,2-C] Pyridones and Related Heterocyclic Compounds as Pharmaceutical Agents for Treating Disorders Responsive to Apoptosis, Antiproliferation or Vascular Disruption, and the Use Thereof | BAX, CASP3, CASP7 | SMN1; SMN2 1792/4885HTT 4157/4885MAPT 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.